Stay updated with breaking news from Bronwen shaw. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
email article Increased access to allogeneic hematopoietic cell transplant (HCT) is feasible for patients who lack an HLA-matched donor with the use of post-transplant cyclophosphamide (PTCy), according to a prospective phase II study. Use of PTCy resulted in an overall survival rate of 76% at 1 year, as well as a low incidence of severe acute graft-versus-host-disease (GVHD), in patients almost half of whom were ethnic minorities who did not have a well-matched donor in the family or in donor registries, reported Bronwen Shaw, MD, PhD, of the Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin in Milwaukee, and colleagues. ....
Results of Multicenter Clinical Trial Sponsored by National Marrow Donor Program/Be The Match published in Journal of Clinical Oncology apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
National Marrow Donor Program/Be The Match Announce Plan to Launch ACCESS Clinical Trial apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.